SP16 SERPIN-like Peptide Administration in Healthy Individuals

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Participants

In brief

This study is a randomized, double-blind, placebo-controlled Phase 1 Clinical Trial of 24 healthy individuals to test the safety, tolerability and pharmacokinetics of a single subcutaneous administration of Serpin Peptide 16 (SP16), a Serine Protease Inhibitor (Serpin)-like, small peptide agonist of the Low Density Lipoprotein Receptor-like Protein 1 (LRPP1) hypothesized to have anti-inflammatory activity.

Key facts

Study ID
NCT03651089
Run by
Serpin Pharma, LLC
People needed
24
Starts
2018-07-16
Expected to finish
2019-01-23
Last updated by the study team
2021-07-28

Who can join

Age: 18 and older, up to 59. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.